MDS 2023 | Developing effective methods to study QoL in clinical trials in MDS
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, offers insight into patient-reported outcome (PRO) measures in clinical trials which can be used to understand the burden of disease and treatment from the unique patient perspective. Dr Efficace addresses the need to design trials that better assess the quality of life (QoL), with high-quality methodological standards for data collection and analysis to yield meaningful data. In the context of clinical trials for myelodysplastic syndromes (MDS), Dr Efficace highlights pragmatism and flexibility to maximize the chances of detecting QoL differences across lines of therapy. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy/Advisory Board: Abbvie, Syros, Incyte, Janssen
